Reproductive Sciences

, Volume 19, Issue 1, pp 86–91 | Cite as

Dehydroepiandrosterone (DHEA) Inhibition of Monocyte Binding by Vascular Endothelium Is Associated With Sialylation of Neural Cell Adhesion Molecule

  • Anna-Maria Curatola
  • Kui Huang
  • Frederick NaftolinEmail author
Original Articles


Rationale: Adhesion of monocytes to vascular endothelium is necessary for atheroma formation. This adhesion requires binding of endothelial neural cell adhesion molecule (NCAM) to monocyte NCAM. NCAM:NCAM binding is blocked by sialylation of NCAM (polysialylated NCAM; PSA-NCAM). Since estradiol (E2) and dihydrotestosterone (DHT) induced PSA-NCAM and decreased monocyte adhesion, in consideration of possible clinical applications we tested whether their prohormone dehydroepiandrosterone (DHEA) has similar effects. Experimental: (1) DHEA was administered to cultured human coronary artery endothelial cells (HCAECs) from men and women. Monocyte binding was assessed using fluorescence-labeled monocytes. (2) HCEACs were incubated with E2, DHT, DHEA alone, or with trilostane, fulvestrant or flutamide. Expression of PSA-NCAM was assessed by immunohistochemistry and Western blotting. Results: Dehydroepiandrosterone inhibited monocyte adhesion to HCAECs by ≥50% (P < .01). Fulvestrant or flutamide blockade of DHEA’s inhibition of monocyte binding appeared to be gender dependent. The DHEA-induced expression of PSA-NCAM was completely blocked by trilostane. Conclusions: In these preliminary in vitro studies, DHEA increased PSA-NCAM expression and inhibited monocyte binding in an estrogen- and androgen receptor-dependent manner. Dehydroepiandrosteroneappears to act via its end metabolites, E2 and DHT. Dehydroepiandrosterone could furnish clinical prevention against atherogenesis and arteriosclerosis.


atherosclerosis heart disease coronary estrogen androgen adhesion NCAM PSA-NCAM 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.CrossRefGoogle Scholar
  2. 2.
    Kiss JZ, Rougon G. Cell biology of polysialic acid. Curr Opin Neurobiol. 1997;7(5):640–646.CrossRefGoogle Scholar
  3. 3.
    Tan O, Fadiel A, Naftolin F, et al. Estrogen regulates posttranslational modification of neural cell adhesion molecule (NCAM) during the estrogen-induced gonadotrophin surge (EIGS). Endocrinology. 2009;150(6):2783–2790.CrossRefGoogle Scholar
  4. 4.
    Park H, Pagan L, Tan O, et al. Estradiol regulates expression of polysialated neural cell adhesion molecule by human vascular endothelial cells. Reprod Sci. 2010;17(12):1090–1098.CrossRefGoogle Scholar
  5. 5.
    Choi SD, Steinberg EM, Lee HH, Naftolin F. The timing hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. Menopause. 2011;18(2):230–236.PubMedGoogle Scholar
  6. 6.
    Tsuchiya S, Kobayashi Y, Goto Y, et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 1982;42(4):1530–1536.PubMedGoogle Scholar
  7. 7..
    Weissman A, Horowitz E, Ravhon A, Golan A, Levran D. Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol Endocrinol. 2011 Apr 18. 27(12): 1014–1017.CrossRefGoogle Scholar
  8. 8.
    Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric. 2010;13(4):314–316.CrossRefGoogle Scholar
  9. 9.
    Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. Prog Brain Res. 2010;181:177–192.CrossRefGoogle Scholar
  10. 10.
    Easterling WE Jr, Simmer HH, Dignam WJ, Frankland MV, Naftolin F. Neutral C19-steroids and steroid sulfates in human pregnancy. II. Dehydroepiandrosterone sulfate, 16-alpha-hydroxy dehydroepiandrosterone, and 16-alpha-hydroxydehydroepiandro sterone sulfate in maternal and fetal blood of pregnancies with anencephalic and normal fetuses. Steroids. 1966;8(2):157–178.CrossRefGoogle Scholar
  11. 11.
    Hopper BR, Yen SS. Circulating concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate during puberty. J Clin Endocrinol Metab. 1975;40(3):458–461.CrossRefGoogle Scholar
  12. 12.
    Perrini S, Laviola L, Natalicchio A, Giorgino F. Associated hormonal declines in aging: DHEAS. J Endocrinol Invest. 2005;28(3 Suppl):85–93.PubMedGoogle Scholar
  13. 13.
    Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998;49(4):421–432.CrossRefGoogle Scholar

Copyright information

© Society for Reproductive Investigation 2012

Authors and Affiliations

  • Anna-Maria Curatola
    • 1
  • Kui Huang
    • 1
  • Frederick Naftolin
    • 1
    • 2
    Email author
  1. 1.Department of Obstetrics and GynecologyNew York UniversityNew YorkUSA
  2. 2.Department of Obstetrics and GynecologyNYU Langone Medical CenterNew YorkUSA

Personalised recommendations